A Phase 3 interventional study of Dexmedetomidine and Normal saline in Ventricular Tachycardia, Ventricular Arrhythmias and Ventricular Fibrillation, sponsored by Ottawa Heart Institute Research Corporation. Recruiting at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-07.
Sponsored by Ottawa Heart Institute Research Corporation · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 154 studies in Tachycardia, Ventricular with a site in United States — 34 open to participants now, 40 under way, 2 of them phase 3. Tachycardia, Ventricular · United States.
Among the 154 studies in Tachycardia, Ventricular with a site in United States, this one is the 27th largest by planned enrollment of the 107 interventional ones that give a count, is one of 7 that started in 2024, is one of 13 in phase 3, reaches primary completion later than 15 of the 39 other live ones, and was the 136th registered.
452 studies on the registry are indexed under Tachycardia, Ventricular; 121 are open to participants now.
Browse Tachycardia, Ventricular studies →34 of the 154 studies in Tachycardia, Ventricular with a site in United States are open now. Recruiting first, the newest first:
Medtronic Cardiac Ablation Solutions · Sites in United States
Ages 18–85
Adagio Medical · Sites in United States, Canada
Ages 18+
AtaCor Medical, Inc. · Sites in United States, Netherlands
Ages 18+
Cardurion Pharmaceuticals, Inc. · Sites in United States, Canada, France and 3 more countries
Ages 18–99
Thermedical, Inc. · Sites in United States, Canada
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 86 Tachycardia, Ventricular studies recruiting now, 67 (78%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
154 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 13 · Phase 3 15 · Phase 4 8
First in 1995; this study’s year is marked. 7 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 192 is above the median of 70 across 281 interventional studies indexed under Tachycardia, Ventricular.
Median enrollment 60 across the 107 interventional studies, 142 across the 47 observational. Of the 99 that completed or were terminated, 51 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
52 of 154 have an industry lead sponsor. The 10 most frequent:
Ottawa Heart Institute Research Corporation is the lead sponsor of 182 studies on the registry; 42 are open to participants now.
Ottawa Heart Institute Research Corporation has 4 studies filed under Tachycardia, Ventricular — fewer than ten, so there is no comparison to draw.
13 of the studies in Tachycardia, Ventricular with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06281977Phase 3Ottawa Heart Institute Research CorporationStudy Evaluating Dexmedetomidine in the Acute Treatment of Electrical Storm | 2027-05-08 |
| NCT06703489Medtronic Cardiac Ablation SolutionsSafety and Performance Assessment of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia (Sphere-9 VT EFS) | 2026-11 |
| NCT06138873Rush University Medical CenterAblation-Index Guided Scar-Mediated Ventricular Tachycardia Ablation in Patients With Ischemic Cardiomyopathy | 2026-11-23 |
| NCT04520347University of California, Los AngelesIVTCC 2.0: A Prospective Multicenter Ventricular Tachycardia Catheter Ablation Registry | 2026-12 |
| NCT06747013Vivek ReddyTreatment of Focal Ventricular Tachycardias Using a Pulsed Field Ablation From a Point Ablation Catheter Short Title FOCUS-PFA | 2027-02 |
Add all 13 to your calendar (.ics) → With an account.
Among the 154 studies in Tachycardia, Ventricular with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to determine if there is a meaningful benefit to using the sedative medication dexmedetomidine in the acute treatment of patients with recurrent ventricular arrhythmias, known as electrical storm. This will be a multi-centre, double-blinded, placebo-controlled, randomized trial. Patients with electrical storm will be randomized to receive 48 to 72 hours of dexmedetomidine or placebo as part of their initial treatment in an intensive care unit.
Electrical storm (ES), defined as three or more sustained or treated ventricular arrhythmias in a 24-hour period, is a life-threatening condition that is associated with significant short- and long-term mortality. Autonomic dysfunction from increased sympathetic tone and the catecholamine surge from defibrillator shocks can precipitate recurrent ventricular arrhythmias and exacerbate ES. Although the mainstay of treatment are anti-arrhythmic drugs, sedative agents and procedures are commonly used to decrease sympathetic tone. These therapies have been studied in refractory ES but the benefit of early sedation remains unclear.
Alpha-2 agonism with dexmedetomidine can provide conscious sedation without the need for mechanical ventilation. Dexmedetomidine has been found to reduce ventricular arrhythmia events in non-ES patients in the intensive care unit and in the peri-operative period. Its antiarrhythmic properties are thought to be due to catecholamine suppression, prolonging electrical refractory periods, and increasing vagal tone. Its rapid onset and favorable safety profile render alpha-2 agonism with dexmedetomidine a potentially valuable therapy for patients with ES.
This study is a multi-centre, double-blinded, placebo-controlled, randomized trial that will evaluate the effectiveness of dexmedetomidine in the acute treatment of ES. Consecutive patients admitted to an intensive care unit will be randomized to receive dexmedetomidine or placebo at the time of presentation. The study drug will be titrated to a maintenance dose and continued for 48 hours before being weaned.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- All patients admitted to an intensive care unit with electrical storm over the age of 18 years will be approached for enrollment.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to receive dexmedetomidine will be started at a dose of 0.3 mcg/kg/hr and titrated to a target dose of 1.0 mcg/kg/hr. Once the participant reaches their maximum tolerated dose (as decided by the blinded treating physician), they will continue treatment for 48 ± 6 hours. This will be followed by a weaning phase that will similarly be at the discretion of the treating physician.
Drug: Dexmedetomidine
Participants randomized to receive placebo will be started on normal saline. In similar fashion to the active comparator, participants will be titrated to their maximal tolerated dose, continue treatment for 48 ± 6 hours, and be weaned at the discretion of the blinded treating physician.
Drug: Normal saline
Dose range: 0.3 mcg/kg/hr to 1 mcg/kg/hr.
Also known as: Precedex
Programed as dexmedetomidine on infusion pump.
The primary outcome is a composite of the following: 1. All-cause in-hospital death AND/OR 2. Any in-hospital ventricular arrhythmia requiring treatment after study drug initiation.
Defined as anytime after the participant starts receiving dexmedetomidine or normal saline placebo
Time frame: Duration of index hospitalization - an average of 2 weeks
All-cause in-hospital death
Defined as anytime after the participant starts receiving dexmedetomidine or normal saline placebo
Time frame: Duration of index hospitalization - an average of 2 weeks
Ventricular arrhythmia requiring treatment after study drug initiation
Defined as anytime after the participant starts receiving dexmedetomidine or normal saline placebo
Time frame: Duration of index hospitalization - an average of 2 weeks
Resuscitated cardiac arrest after study drug initiation
Defined as anytime after the participant starts receiving dexmedetomidine or normal saline placebo
Time frame: Duration of index hospitalization - an average of 2 weeks
Renal failure requiring new initiation of renal replacement therapy after study drug initiation
Defined as anytime after the participant starts receiving dexmedetomidine or normal saline placebo
Time frame: Duration of index hospitalization - an average of 2 weeks
Intubation following study drug initiation
Defined as anytime after the participant starts receiving dexmedetomidine or normal saline placebo
Time frame: Duration of index hospitalization - an average of 2 weeks
Length of stay in the intensive care unit
Defined as anytime after the participant starts receiving dexmedetomidine or normal saline placebo
Time frame: Duration of index hospitalization - an average of 2 weeks
Length of stay in hospital
Defined as anytime after the participant starts receiving dexmedetomidine or normal saline placebo
Time frame: Duration of index hospitalization - an average of 2 weeks
Need for mechanical circulatory support device after study drug initiation
Defined as anytime after the participant starts receiving dexmedetomidine or normal saline placebo
Time frame: Duration of index hospitalization - an average of 2 weeks
Ventricular Arrhythmia requiring treatment only during active study drug treatment
Defined as anytime the participant is receiving dexmedetomidine or normal saline placebo
Time frame: Duration of index hospitalization - an average of 2 weeks
Pacing or treatment with isoproterenol for treatment of bradyarrhythmia after study drug initiation.
Defined as anytime after the participant starts receiving dexmedetomidine or normal saline placebo
Time frame: Duration of index hospitalization - an average of 2 weeks
Plan to share: Yes — The study data, protocol, SAP, ICF, and CSR will be made available at study completion/publication.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Study completion
Access criteria: The above will be made publicly available
Started May 2024 (actual). Primary completion is estimated for May 2027, 36 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexmedetomidine
Ottawa Heart Institute Research Corporation →